Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 17

Expert digest

Hives After CJC-1295 and Ipamorelin

Hives after CJC-1295 and ipamorelin may signal hypersensitivity, but the small human record cannot identify a cause or estimate the risk.

24 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Expert digest

How Many Peptides Is Too Many?

No study defines a safe peptide count after hip replacement. A six-compound mix adds untested interactions and makes adverse effects harder to trace.

24 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

MASLD Pharmacotherapy: Clinical Review

A 2026 review frames MASLD drug choice around fibrosis stage and metabolic phenotype, while trials and US labels keep the approved options distinct.

24 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Semaglutide in Two Very Young Children

A two-child case series reports lower BMI-SDS with semaglutide, but no control group and no approval for this preschool age range.

24 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Tirzepatide response over 12 months

A 249-person tirzepatide cohort reported large 12-month losses, but available-case follow-up and nonrandom dosing limit the conclusion.

24 Oct 2026 · PeptideMethods Editorial Team · 6 min read
Trial readouts

Apothecary tirzepatide recall explained

FDA records show a 22-vial compounded tirzepatide recall over sterility assurance. Here is what the Class II action does and does not show.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GIP Signaling Across Two Fat Depots

A narrative review finds that GIP effects differ by fat depot and metabolic context, while the human mechanism remains unsettled.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Oral Effects of GLP-1 and GIP Drugs

A 2026 protocol sets out how researchers will map reported oral effects of GLP-1 and dual GLP-1/GIP drugs. It presents no review findings.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Drugs and Reproductive Health

A 2026 review maps contraception, fertility, and pregnancy questions for GLP-1 drugs but does not provide new trial evidence.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Mounjaro access and U.S. biotech rules

A STAT roundup paired a Belgian Mounjaro coverage refusal with a U.S. China-biotech proposal. The two policy stories require separate readings.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide and Decision-Making in MDD

A small randomized trial analysis found changes in modeled choice behavior, but it did not show that semaglutide treats depression.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide Microneedle Rat Study

A PVA microneedle patch delivered semaglutide and changed weight-related outcomes in rats, with no human efficacy evidence.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read